(Reuters) - Drugmaker Eli Lilly said on Tuesday it is launching an artificial intelligence and machine learning platform that provides biotech companies access to drug discovery models trained on ...

Sept 9 (Reuters) - Drugmaker Eli Lilly (LLY.N), opens new tab said on Tuesday it is launching an artificial intelligence and machine learning platform that provides biotech companies access to drug ...

Acclaimed actress, author, and advocate Julianne Moore joins cause in the United States to encourage early, ongoing brain health conversations between people and their doctors Nearly four in five ...

A federal appeals court on Thursday rejected Eli Lilly’s appeal of an $183.7 million judgment won by a whistleblowing lawyer and pharmacist who accused the drugmaker of defrauding Medicaid. The 7th ...

Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Eli Lilly (NYSE:LLY) must pay $183.7M as damages in a lawsuit alleging that the Indiana-based drugmaker defrauded the Medicaid drug pricing program, a federal appeals court ruled on Thursday, ...

Takeda (NYSE:TAK) said on Thursday that Rhonda Pacheco, who was the group vice president of U.S. cardiometabolic health at Eli Lilly (NYSE:LLY), will join the company as president of its U.S. Business ...

insitro, a pioneer in machine learning for drug discovery and development, today announced a new collaboration with Eli Lilly and Company (Lilly) to develop advanced machine learning models that can ...

i Controlled for family-wise type 1 error rate. ii Percentage of participants achieving body weight reductions of ≥20% with orforglipron 6 mg was not controlled for ...

Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy, just announced plans to cut 11% of its workforce as competitors like Eli Lilly continue to ...

Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 agonists for diabetes, with new data for Mounjaro on cardiovascular outcomes. The results of the SURPASS-CVOT trial showed ...